Literature DB >> 23569679

Subtrochanteric insufficiency fractures associated with bisphosphonate use: 2 case reports and review.

J Kearse1, M Armitage, M Suk, B H Berrey.   

Abstract

Insufficiency fractures are beginning to emerge in case reports of patients on long-term bisphosphonate therapy. The side effects associated with the long-term use of bisphosphonates were once thought to only involve renal and gastrointestinal (GI) toxicity and osteonecrosis of the jaw, but it is becoming clear that the very condition bisphosphonates were meant to treat could be causing another, trading insufficiency fractures for another type of insufficiency fracture. We review the literature concerning this surprising trend in addition to providing 2 case reports and conclude that these fractures do occur, that they can heal uneventfully, and that further research is needed to determine optimum treatment algorithms concerning duration of treatment and to weigh the potential benefits and morbidity of bisphosphonate treatment.

Entities:  

Keywords:  fragility fractures; geriatric medicine; metabolic bone disorders; osteoporosis; pharmacology; trauma surgery

Year:  2011        PMID: 23569679      PMCID: PMC3597311          DOI: 10.1177/2151458511413764

Source DB:  PubMed          Journal:  Geriatr Orthop Surg Rehabil        ISSN: 2151-4585


  8 in total

Review 1.  Overview of osteoporosis: pathophysiology and determinants of bone strength.

Authors:  Christopher M Bono; Thomas A Einhorn
Journal:  Eur Spine J       Date:  2003-09-12       Impact factor: 3.134

2.  Long-term safety of bisphosphonates.

Authors:  Susan M Ott
Journal:  J Clin Endocrinol Metab       Date:  2005-03       Impact factor: 5.958

3.  Severely suppressed bone turnover: a potential complication of alendronate therapy.

Authors:  Clarita V Odvina; Joseph E Zerwekh; D Sudhaker Rao; Naim Maalouf; Frank A Gottschalk; Charles Y C Pak
Journal:  J Clin Endocrinol Metab       Date:  2004-12-14       Impact factor: 5.958

4.  Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.

Authors:  S-K Goh; K Y Yang; J S B Koh; M K Wong; S Y Chua; D T C Chua; T S Howe
Journal:  J Bone Joint Surg Br       Date:  2007-03

5.  Low-energy femoral shaft fractures associated with alendronate use.

Authors:  Andrew S Neviaser; Joseph M Lane; Brett A Lenart; Folorunsho Edobor-Osula; Dean G Lorich
Journal:  J Orthop Trauma       Date:  2008 May-Jun       Impact factor: 2.512

Review 6.  The current treatment--a survey of osteoporotic fracture treatment. Osteoporotic spine fractures: the spine surgeon's perspective.

Authors:  Paul F Heini
Journal:  Osteoporos Int       Date:  2004-09-09       Impact factor: 4.507

7.  An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

Authors:  Ernest Beng Kee Kwek; Seo Kiat Goh; Joyce Suang Bee Koh; Meng Ai Png; Tet Sen Howe
Journal:  Injury       Date:  2008-01-28       Impact factor: 2.586

8.  Case reports: two femoral insufficiency fractures after long-term alendronate therapy.

Authors:  Arkan S Sayed-Noor; Göran O Sjödén
Journal:  Clin Orthop Relat Res       Date:  2009-02-06       Impact factor: 4.176

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.